Contact Us
  • Choose License Type

Global Anti-inflammatory Drugs Market, by Drug Type (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Immune Selective Anti-inflammatory Derivatives (ImSAIDs), Anti-inflammatory Biologics, and Corticosteroids), by Application (Arthritis, Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Inflammatory Bowel Disease (IBD), Gout, and Others), by Route of Administration (Oral, Topical, Injection, and Inhalation), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 79,830.2 million in 2020 and is expected to exhibit a CAGR of 8.6% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Research & development by market players to augment the market growth

Major players in the market are focused on research and development of novel anti-inflammatory drugs, which is expected to boost the market growth. For instance, on 27th February 2020, Dr. Reddy’s Laboratories Ltd., a pharmaceutical company, launched generic versions of Naproxen and Esomeprazole Magnesium, an anti-inflammatory drugs delayed-release tablets, a therapeutic equivalent generic version of Vimovo (Naproxen and Esomeprazole Magnesium) delayed-release tablets approved by the U.S. Food and Drug Administration (U.S. FDA).

Global Anti-inflammatory Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in over 65.87 million infected individuals worldwide, as of December 6, 2020.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channel, and by its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of such drugs from one place to another.

Moreover the COVID-19 pandemic has impacted the supply of raw materials and potent compounds, which are used for manufacturing drugs such as anti-inflammatory drugs, this is expected to hamper the market growth in the near future.

Browse 40 Market Data Tables and 35 Figures spread through 200 Pages and in-depth TOC on “Anti-inflammatory Drugs Market – by Drug Type (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Immune Selective Anti-inflammatory Derivatives (ImSAIDs), Anti-inflammatory Biologics, and Corticosteroids), by Application (Arthritis, Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Inflammatory Bowel Disease (IBD), Gout, and Others), by Route of Administration (Oral, Topical, Injection, and Inhalation), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027”

To know the latest trends and insights prevalent in the global anti-inflammatory drugs market, click the link below:

https://www.coherentmarketinsights.com/market-insight/anti-inflammatory-drugs-market-4327

Key players in the market are focusing on novel products approvals and launches for anti-inflammatory drugs. For instance, in July 2018 Aurobindo Pharma received the U.S. Food and Drug Administration (U.S. FDA) to manufacture and market Ibuprofen capsules, which is used to relieve pain and reduce fever. This capsules are generic equivalent of Pfizer's Advil liqui-gels capsules.

Key Takeaways of the Global Anti-inflammatory Drugs Market:

  • The global anti-inflammatory drugs market is expected to exhibit a CAGR of 8.6% during the forecast period, owing to rising incidence of chronic diseases. For instance, according to the facts and figures published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) in July 2019, reports that 65 million people suffer from chronic obstructive pulmonary disease (COPD) each year globally, which makes it the third leading cause of death worldwide.
  • Among drug type, nonsteroidal anti-inflammatory drugs (NSAIDs) segment held a dominant position in the anti-inflammatory drugs market in 2019, owing to increasing product launches of nonsteroidal anti-inflammatory drugs. For instance, in January 2020, Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on hospital acute care, launched Caldolor (ibuprofen) injection in a ready-to-use bag that may be administered without dilution for pain relief. This launch follows U.S. FDA approval in 2019 for the product's new delivery method. Caldolor is a nonsteroidal anti-inflammatory drug, which is the only method of treatment for mild-moderate pain or as part of a multi-modal treatment for severe pain.
  • Among application, arthritis segment held a dominant position in the anti-inflammatory drugs market in 2019, owing to rising cases of arthritis globally. For instance, according to an article published by the Morbidity and Mortality Weekly Report, an epidemiological digest Centers for Disease Control and Prevention (CDC) in 2017, reports that around 54.4 million adults in the U.S. (22.7% of all adults) had doctor-diagnosed arthritis.
  • Among route of administration, topical segment held a dominant position in the anti-inflammatory drugs market in 2019, as topical anti-inflammatory drugs stays close to the site of application, so that blood level and more remote tissues remain low.
  • Among distribution channel, hospital pharmacies segment held a dominant position in the anti-inflammatory drugs market in 2019, as partnerships and agreements of hospitals with specialty pharmacies services providers are expected to drive the segment growth during the forecast period.
  • Key players operating in the global anti-inflammatory drugs market include Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Merck & Company, Inc., Novartis AG, Amgen, Inc., AstraZeneca plc, Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Biogen Inc., Sun Pharmaceutical Industries Ltd, Mylan, Inc., Aurobindo Pharma Limited, and Dr. Reddy’s Laboratories among others.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner